https://www.yiliao.com/index.php?action=history&feed=atom&title=FOLFIRI
FOLFIRI - 版本历史
2026-04-09T23:09:14Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=FOLFIRI&diff=316434&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-02-04T14:17:57Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>FOLFIRI</strong> 是一种用于治疗转移性结直肠癌（mCRC）的标准全身<strong>化疗方案</strong>。其名称由三种组成药物的首字母缩写而成：<strong>Fol</strong>inic acid（亚叶酸钙/甲酰四氢叶酸）、<strong>F</strong>luorouracil（氟尿嘧啶/5-FU）和 <strong>Iri</strong>notecan（伊立替康）。<br />
<br>FOLFIRI 通常作为 mCRC 的一线或二线治疗方案。大量临床研究（如 Tournigand 试验）证实，FOLFIRI 与另一种标准方案 <strong>[[FOLFOX]]</strong>（含奥沙利铂）在总生存期（OS）上效果相当，但<strong>毒性谱</strong>截然不同。因此，临床决策常基于患者的既往毒性反应（如是否已有神经毒性）来选择。FOLFIRI 常与靶向药物（如 <strong>[[贝伐珠单抗]]</strong> 或 <strong>[[西妥昔单抗]]</strong>）联合使用以进一步提高疗效。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">FOLFIRI</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">5-FU + Leucovorin + Irinotecan (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="width: 100px; height: 100px; background-color: #e2e8f0; border-radius: 50%; margin: 0 auto; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em;"><br />
<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">肠癌化疗基石方案</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">方案参数</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[Irinotecan]] (CPT-11)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">基石药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[5-FU]] + [[LV]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">给药周期</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">每 2 周 (q2w)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">输注方式</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">静脉推注 + 持续泵注</td><br />
</tr><br />
<br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">临床特征</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">特定毒性</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #e11d48;">迟发性腹泻 • 胆碱能综合征</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">脱发风险</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">较高 (明显高于FOLFOX)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">主要竞品</th><br />
<td style="padding: 6px 12px; color: #0f172a;">[[FOLFOX]] • [[XELIRI]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">药物协同机制</h2><br />
<br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
FOLFIRI 利用不同机制的药物协同攻击癌细胞的 DNA 复制过程。<br />
</p><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>伊立替康 (Irinotecan)：</strong> 是一种拓扑异构酶 I 抑制剂。它在体内被代谢为活性更强（约1000倍）的 <strong>SN-38</strong>，通过抑制 DNA 复制过程中的解旋和修复，导致 DNA 双链断裂和细胞死亡。</li><br />
<li style="margin-bottom: 12px;"><strong>5-FU 与 亚叶酸钙 (LV)：</strong> 5-FU 是抗代谢药物，抑制胸苷酸合成酶。LV（亚叶酸钙）本身无抗肿瘤活性，但它能稳定 5-FU 与酶的结合复合物，从而显著<strong>增强 5-FU 的疗效</strong>。</li><br />
<li style="margin-bottom: 0;"><strong>给药顺序：</strong> 通常先滴注伊立替康和亚叶酸钙，随后给予 5-FU 推注，最后接 46-48 小时的 5-FU 持续泵注。持续输注对于维持 5-FU 的血药浓度至关重要。</li><br />
</ul><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">FOLFIRI vs. FOLFOX：如何选择？</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
二者疗效相当，选择主要取决于对副作用的管理偏好。<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">特性</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 40%;">FOLFIRI (含伊立替康)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 40%;">FOLFOX (含奥沙利铂)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">核心毒性</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #e11d48;"><strong>胃肠道毒性 (腹泻)</strong>、脱发</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>周围神经毒性</strong> (手脚麻木)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">适用场景</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">适合已有神经病变（如糖尿病）的患者。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">适合肠道功能差或惧怕脱发的患者。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">UGT1A1 基因</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">需检测。<strong>UGT1A1*28</strong> 纯合突变者需降低剂量，否则易发生严重腹泻/粒缺。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">通常无需检测该基因。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">副作用管理：两个“腹泻”</h2><br />
<br />
<ul style="padding-left: 25px; color: #334155; margin-top: 15px;"><br />
<li style="margin-bottom: 12px;"><strong>急性胆碱能综合征 (早发性腹泻)：</strong> 发生于输注伊立替康时或结束后 24 小时内。表现为出汗、腹痛、流泪、瞳孔缩小。这是由于伊立替康抑制乙酰胆碱酯酶所致。<strong>处理：</strong> 皮下注射阿托品可迅速缓解。</li><br />
<li style="margin-bottom: 12px;"><strong>迟发性腹泻：</strong> 发生于用药 24 小时后（通常 5-7 天）。这是 SN-38 对肠粘膜的直接毒性。<strong>处理：</strong> 一旦发生，必须立即服用高剂量<strong>[[洛哌丁胺]] (Loperamide)</strong>，直至腹泻停止 12 小时。若脱水严重需住院补液。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Douillard JY, et al. (2000).</strong> <em>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.</em> <strong>[[The Lancet]]</strong>. <br><br />
<span style="color: #475569;">[点评]：确立 FOLFIRI 方案地位的基石研究。证明了在 5-FU 基础上加入伊立替康可显著延长 OS。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Tournigand C, et al. (2004).</strong> <em>FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.</em> <strong>[[Journal of Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：经典的 GERCOR 研究。证明了先用 FOLFIRI 后用 FOLFOX，与反之顺序，最终的总生存期是一样的。确立了两种方案互为二线挽救治疗的策略。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Van Cutsem E, et al. (2011).</strong> <em>Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. <br><br />
<span style="color: #475569;">[点评]：CRYSTAL 试验。证明了 FOLFIRI 联合西妥昔单抗在 KRAS 野生型患者中的巨大获益。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
肿瘤化疗方案 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">上级分类</td><br />
<td style="padding: 10px 15px; color: #334155;">[[化疗]] • 结直肠癌标准治疗</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心组分</td><br />
<td style="padding: 10px 15px; color: #334155;">[[伊立替康]] • [[氟尿嘧啶]] • [[亚叶酸钙]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">衍生/变体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FOLFIRINOX]] (加奥沙利铂，胰腺癌用) • [[XELIRI]] (口服版)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020